Product claims may differ from country to country based on regulations and product approvals. Please contact your country representative for further details.

»  Ricerca


Ricerca avanzata

»  News-Alert

Subscribe to our e-mail newsletter to get our latest news and dates by e-mail

Subscribe / Unsubscribe


Software-Update: Thermo Scientific B·R·A·H·M·S Fast Screen pre I plus V 1.3 for all KRYPTOR systems

Thermo Scientific Biomarkers has brought an Update of the CE marked prenatal screening software B·R·A·H·M·S Fast Screen pre I plus onto the market. The new version 1.3 of the prenatal screening software is available as of November 2011 - currently deliverable in the following languages: German, English and French.


Thermo Scientific Biomarkers launches new assay: Thermo Scientific B·R·A·H·M·S TRAK human KRYPTOR

Thermo Scientific Biomarkers launched the automated TRAK human KRYPTOR assay in countries that accept CE certification. This assay is highly specific for the autoimmune disorder Graves´ disease.


B·R·A·H·M·S-Forum: Workshop on thyroid cancer big success

Hennigsdorf / Berlin 24.11.2009. At the invitation of B·R·A·H·M·S over 50 medics and scientists made their way to Berlin on November 6 and 7 to get an update on most recent developments in the field of thyroid cancer.


L’autorità garante della concorrenza permette l’acquisizione di B·R·A·H·M·S da parte di Thermo Fisher Scientific

Thermo Fisher Scientific Inc. (NYSE: TMO) ha acquisito tutte le quote di B·R·A·H·M·S Holding GmbH. L’accordo contrattuale è stato reso noto all’inizio di settembre. Ora, dopo un esame durato quattro settimane, le autorità di vigilanza competenti hanno espresso la loro approvazione.


The struggle against bacterial resistance and increasing medical costs:

ProHOSP study demonstrates the value of Procalcitonin marker for lower respiratory tract infections


B·R·A·H·M·S e Thermo Fisher Scientific uniscono le proprie forze creando un centro leader nella diagnostica specializzata.

B·R·A·H·M·S annuncia la sottoscrizione di uno Share Purchase Agreement (SPA) con Thermo Fisher Scientific Inc. (NYSE: TMO) per l’acquisizione del 100% del capitale azionario di B·R·A·H·M·S Holding GmbH, equivalente a EUR 330 milioni (circa USD 470 milioni) inclusi debiti e altre passività. Il perfezionamento della transazione, soggetta all’approvazione delle autorità competenti, è previsto per la fine di settembre 2009.


Company Event on Friday, September 4th 2009!


BRAHMS KRYPTOR compact is certified by the Fetal Medicine Foundation (FMF)

Hennigsdorf, Germany, 16-07-2009. The Fetal Medicine Foundation (FMF) confirmed that BRAHMS KRYPTOR compact is fulfilling the requirements for first trimester biochemical screening.


New Cardiac Marker Copeptin accelerates Diagnosis of Acute Myocardial Infarction (AMI)

Hennigsdorf, July 2, 2009. The novel biomarker Copeptin can improve patient management in the Emergency Department (ED). The study “Incremental Value of Copeptin for Rapid Rule Out of Acute Myocardial Infarction (AMI)” was recently published in the Journal of the American College of Cardiology (JACC).

Pagina: 2